<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">Metabolic syndrome</z:e> is characterized by a combination of <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, and <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This multifaceted syndrome is often accompanied by a hyperdynamic circulatory state characterized by <z:e sem="disease" ids="C0497247,C0020538" disease_type="Disease or Syndrome;Finding" abbrv="">increased blood pressure</z:e>, total blood volume, cardiac output, and metabolic tissue demand </plain></SENT>
<SENT sid="2" pm="."><plain>Experimental, epidemiological, and clinical studies have demonstrated that patients with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> have significantly elevated <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> and mortality rates </plain></SENT>
<SENT sid="3" pm="."><plain>One of the main and frequent complications seen in <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> is <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The primary endpoints of cardiometabolic risk are coronary and <z:hpo ids='HP_0004950'>peripheral arterial disease</z:hpo>, <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo>, <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>, and <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Alterations in expression and/or functioning of several key proteins involved in regulating and maintaining ionic homeostasis can cause cardiac disturbances </plain></SENT>
<SENT sid="6" pm="."><plain>One such group of proteins is known as <z:chebi fb="0" ids="8925">ryanodine</z:chebi> receptors (intracellular calcium release channels), which are the major channels through which Ca(2+) ions leave the sarcoplasmic reticulum, leading to cardiac muscle contraction </plain></SENT>
<SENT sid="7" pm="."><plain>The economic cost of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and its associated complications has a significant effect on health care budgets </plain></SENT>
<SENT sid="8" pm="."><plain>Improvements in body weight, blood <z:chebi fb="23" ids="18059">lipid</z:chebi> profile, and <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> can reduce cardiometabolic risk </plain></SENT>
<SENT sid="9" pm="."><plain>However, constant hyperadrenergic stimulation still contributes to the burden of disease </plain></SENT>
<SENT sid="10" pm="."><plain>Normalization of the hyperdynamic circulatory state with conventional therapies is the most reasonable therapeutic strategy to date </plain></SENT>
<SENT sid="11" pm="."><plain>JTV519 (K201) is a newly developed 1,4-<z:chebi fb="0" ids="48684">benzothiazepine</z:chebi> drug with antiarrhythmic and cardioprotective properties </plain></SENT>
<SENT sid="12" pm="."><plain>It appears to be very effective in not only preventing but also in reversing the characteristic myocardial changes and preventing lethal <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>It is also a unique candidate to improve diastolic <z:hpo ids='HP_0001635'>heart failure</z:hpo> in <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
</text></document>